Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when he plans to publish real world evidence on the effectiveness of the respiratory syncytial virus vaccine in the 75-80 cohort; how much such evidence has been collected; and whether such evidence from other countries has been taken into account in consideration of extending eligibility for that vaccine.

The UK Health Security Agency is working on vaccine effectiveness analysis within the 75 to 80-year-old age group for this winter season 2024 to 2025. We are collating data on respitatory syncytial virus (RSV) hospitalisations in England and general practice consultations in a sentinel network.

Data is required from across the entire RSV season to give an accurate estimate of effectiveness. Analyses are therefore likely to take place around the end of the winter season 2024-2025. Publication is expected to follow in due course.

Evidence of effectiveness in all age groups in all countries where data has been made available is being used to inform eligibility considerations. Emerging real-world evidence will be reviewed by the Joint Committee on Vaccination & Immunisation as part of its considerations for a potential extension to the older adults RSV immunisation programme, currently aimed at people aged between 75 and 80 years old, to include people over 80 years old and risk groups.